<DOC>
	<DOCNO>NCT00154388</DOCNO>
	<brief_summary>Exploratory study examine effect ( ) Imatinib mesylate treatment life threaten rare disease know association one Imatinib mesylate -sensitive tyrosine kinase , identify contribution specific protein tyrosine kinase ( PTKs ) specific disease .</brief_summary>
	<brief_title>Phase II Study Imatinib Mesylate Patients With Life Threatening Malignant Rare Diseases</brief_title>
	<detailed_description />
	<mesh_term>Rare Diseases</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients â‰¥ 15 year age Life threaten disease document conventional criterion resistant standard , approve therapy . Experimental documentation functional significance either Abl , Kit ( CD117 ) , PDGFR relevant target tissue ( preferably sample take within 6 week study entry ) . ECOG Performance status 0 , 1 , 2 . Adequate end organ function define : total bilirubin &lt; 1.5 x ULN , SGOT SGPT &lt; 2.5 x UNL ( &lt; 5 x ULN patient hepatic disease ) , creatinine &lt; 1.5 x ULN , ANC &gt; 1.5 x 109/L , platelet &gt; 100 x 109/L . Negative serum urine pregnancy test woman child bear potential ( WOCBP ) within 7 day study initiation . Post menopausal woman must experience amenorrhea least 12 month . Male female patient must use effective birth control method throughout study 3 month study discontinuation . Life expectancy 3 month . Written , voluntary , informed consent retrieval , evaluation investigational use tissue sample . Patients receive investigational agent within 28 day study initiation . Patients another primary malignancy except primary malignancy neither currently clinically significant require active intervention . Patients Grade III/IV cardiac problem define New York Heart Association Criteria ( e.g . congestive heart failure , myocardial infarction within 6 month study ) . Female patient pregnant breastfeeding . Patients another severe and/or life threaten medical disease . Patients acute know chronic liver disease ( e.g . chronic active hepatitis , cirrhosis ) . Patients know diagnosis human immunodeficiency virus ( ( HIV ) infection . Patients receive chemotherapy within 4 week ( 6 week allow nitrosourea , mitomycinC antibody therapy ) prior study entry . Patients major surgery within 2 week prior study entry . Patients significant history noncompliance medical regimen inability grant reliable informed consent . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>adenocarcinoma</keyword>
	<keyword>leiomyosarcoma</keyword>
	<keyword>angiosarcoma</keyword>
	<keyword>synovial sarcoma</keyword>
	<keyword>myelodysplastic syndrome/HES</keyword>
	<keyword>CMML</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>embryonal rhabdomyosarcoma</keyword>
	<keyword>endometrial sarcoma</keyword>
	<keyword>adenoid cystic carcinoma</keyword>
	<keyword>fibromatosis</keyword>
	<keyword>ductal invasive breast carcinoma</keyword>
	<keyword>chondrosarcoma</keyword>
	<keyword>pleural tumor</keyword>
	<keyword>brenner tumor</keyword>
	<keyword>ewing sarcoma</keyword>
	<keyword>round cell tumor</keyword>
	<keyword>seminoma</keyword>
	<keyword>thymic carcinoma</keyword>
	<keyword>malignant melanoma</keyword>
	<keyword>fibrosarcoma breast</keyword>
	<keyword>dermatofibrosarcoma protuberans</keyword>
	<keyword>DFSP</keyword>
	<keyword>ovarian stromal tumor</keyword>
	<keyword>osteosarcoma</keyword>
	<keyword>chorioideal melanoma</keyword>
	<keyword>hemangiopericytoma</keyword>
	<keyword>myelofibrosis</keyword>
	<keyword>liposarcoma</keyword>
	<keyword>SCLC</keyword>
	<keyword>small cell lung carcinoma</keyword>
	<keyword>hypereosinophilic syndrome</keyword>
	<keyword>chronic myelo-monocytic leukemia</keyword>
	<keyword>neurofibrosarcoma</keyword>
	<keyword>mesothelioma</keyword>
	<keyword>malignant mesenchymoma</keyword>
	<keyword>malignant schwannoma</keyword>
	<keyword>mast cell leukemia / mastocytosis</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>malignant histocytoma</keyword>
	<keyword>chordoma</keyword>
</DOC>